
16 February 2022
Goodbody Health Inc.
("Goodbody Health," or the "Company")
Blood testing trial success
Goodbody Health announces successful progress with blood testing.
Goodbody Health (AQSE: GDBY) is pleased to announce the rollout of its plan to introduce blood testing through its existing network of clinics while it continues to contract with more new pharmacies including 15 last week.
This process includes venous blood draws with an in-clinic phlebotomist and Goodbody has launched its own phlebotomy training academy, training up staff within its existing clinic network to allow them to offer in clinic health and wellness blood tests. Newly partnered clinics will also have the opportunity to train up to three members of their staff within the phlebotomy training school.
At the same time the Group continues to bring in innovative technologies into its clinics to offer results to tests such as cholesterol and diabetes delivered in minutes.
These tests help people assess their wellness and determine any lifestyle changes required to live better giving feedback to Goodbody Health to develop the model including additional products and services.
Meanwhile COVID testing revenues are still averaging at over 500 tests per day, remaining strong due to other country entry requirements although the
Geremy Thomas, Executive Chairman, said; "We have set up a model for blood testing, that our partners cannot wait to roll out as they see the benefits for everyone in their local areas, while continuing to provide PCR testing for our customer base."
For further information:
Marc Howells Chief Executive Officer Goodbody Health Inc. +44 (0) 20 7971 1255 enquiries@goodbodyhealth.com |
Anne Tew Chief Financial Officer Goodbody Health Inc. +44 (0) 20 7971 1255 enquiries@goodbodyhealth.com
|
|
AQSE Corporate Adviser Arden Partners plc Antonio Bossi / George Morgan + 44 (0) 20 7614 5900 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.